Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 3 , Pages 238-245 , May 2009

Clinical implications of hypoxia inducible factor in renal cell carcinoma

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106–130
  2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611–1623
  3. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last two decades in the United States: An analysis of surveillance, epidemiology, and end results program data. J Urol. 2002;167(1):57–60
  4. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19(2):148–154
  5. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447–5454
  6. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92(12):5510–5514
  7. Jain S, Maltepe E, Lu MM, et al. Expression of ARNT, ARNT2, HIF1 α, HIF2 α and Ah receptor mRNAs in the developing mouse. Mech Dev. 1998;73(1):117–123
  8. Salceda S, Caro J. Hypoxia-inducible factor 1 α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions (Its stabilization by hypoxia depends on redox-induced changes). J Biol Chem. 1997;272(36):22642–22647
  9. Kallio PJ, Wilson WJ, O'Brien S, et al. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem. 1999;274(10):6519–6525
  10. Sowter HM, Ratcliffe PJ, Watson P, et al. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001;61(18):6669–6673
  11. Srinivas V, Zhang LP, Zhu XH, et al. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor α (HIF-α) proteins. Biochem Biophys Res Commun. 1999;260(2):557–561
  12. McNeill LA, Hewitson KS, Claridge TD, et al. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the β-carbon of Asparagine-803. Biochem. 2002;367:571–575
  13. Freedman SJ, Sun ZY, Poy F, et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 α. Proc Natl Acad Sci USA. 2002;99(8):5367–5372
  14. Land SC, Tee AR. Hypoxia inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR-signaling motif. J Biol Chem. 2007;282:20534–43
  15. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85–90
  16. Lisztwan J, Imbert G, Wirbelauer C, et al. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 1999;13(14):1822–1833
  17. Maxwell PH, Wiesener MS, Chang GW, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275
  18. Aprelikova O, Chandramouli GV, Wood M, et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem. 2004;92(3):491–501
  19. Ivan M, Kondo K, Yang H, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001;292(5516):464–468
  20. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitination complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–472
  21. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997;11(1):72–82
  22. Ryan HE, Lo J, Johnson RS. HIF-1 α is required for solid tumor formation and embryonic vascularization. EMBO J. 1998;17(11):3005–3015
  23. Tian H, Hammer RE, Matsumoto AM, et al. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 1998;12(21):3320–3324
  24. Holmquist L, Jogi A, Pahlman S. Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells. Int J Cancer. 2005;116(2):218–225
  25. Wiesener MS, Jurgensen JS, Rosenberger C, et al. Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J. 2003;17(2):271–273
  26. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys (Evidence for site-specific tumor suppressor function in the nephron). Cancer Cell. 2002;1(5):459–468
  27. Kim CM, Vocke C, Torres-Cabala C, et al. Expression of hypoxia inducible factor-1α and 2α in genetically distinct early renal cortical tumors. J Urol. 2006;175(5):1908–1914
  28. Gu YZ, Moran SM, Hogenesch JB, et al. Molecular characterization and chromosomal localization of a third α-class hypoxia inducible factor subunit, HIF3α. Gene Expr. 1998;7(3):205–213
  29. Maynard MA, Qi H, Chung J, et al. Multiple splice variants of the human HIF-3 α locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem. 2003;278(13):11032–11040
  30. Maynard MA, Evans AJ, Hosomi T, et al. Human HIF-3α4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J. 2005;19(11):1396–1406
  31. Kim WY, Kaelin WG. Molecular pathways in renal cell carcinoma—rationale for targeted treatment. Semin Oncol. 2006;33(5):588–595
  32. Maranchie JK, Vasselli JR, Riss J, et al. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 2002;1(3):247–255
  33. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1(3):237–246
  34. Zimmer M, Doucette D, Siddiqui N, et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL–/– tumors. Mol Cancer Res. 2004;2(2):89–95
  35. Kondo K, Kim WY, Lechpammer M, et al. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003;1(3):E83
  36. Rankin EB, Higgins DF, Walisser JA, et al. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol. 2005;25(8):3163–3172
  37. Hu CJ, Wang LY, Chodosh LA, et al. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol. 2003;23(24):9361–9374
  38. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25(13):5675–5686
  39. Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117(4):1068–1077
  40. Pouyssegur J, Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. Biol Chem. 2006;387(10–11):1337–1346
  41. Haddad JJ, Olver RE, Land SC. Antioxidant/pro-oxidant equilibrium regulates HIF-1α and NF-κ B redox sensitivity (Evidence for inhibition by glutathione oxidation in alveolar epithelial cells). J Biol Chem. 2000;275(28):21130–21139
  42. Haddad JJ, Land SC. A non-hypoxic, ROS-sensitive pathway mediates TNF-α-dependent regulation of HIF-1α. FEBS Lett. 2001;505(2):269–274
  43. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J Biol Chem. 2000;275(35):26765–26771
  44. Jung YJ, Isaacs JS, Lee S, et al. IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17(14):2115–2117
  45. BelAiba RS, Djordjevic T, Bonello S, et al. Redox-sensitive regulation of the HIF pathway under nonhypoxic conditions in pulmonary artery smooth muscle cells. Biol Chem. 2004;385(3/4):249–257
  46. Shiose A, Kuroda J, Tsuruya K, et al. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem. 2001;276(2):1417–1423
  47. Maranchie JK, Zhan Y. Nox4 is critical for hypoxia-inducible factor 2-α transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma. Cancer Res. 2005;65(20):9190–9193
  48. Block K, Gorin Y, Hoover P, et al. NAD(P)H oxidases regulate HIF-2α protein expression. J Biol Chem. 2007;282(11):8019–8026
  49. Isaacs JS, Jung YJ, Mimnaugh EG, et al. Hsp90 Regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem. 2002;277(33):29936–29944
  50. Isaacs JS, Jung YJ, Neckers L. Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1α by modulating an Hsp90-dependent regulatory pathway. J Biol Chem. 2004;279(16):16128–16135
  51. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8(2):143–153
  52. Liu MY, Poellinger L, Walker CL. Up-regulation of hypoxia-inducible factor 2α in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res. 2003;63(10):2675–2680
  53. Semenza GL. Development of novel therapeutic strategies that target HIF-1. Expert opinion on therapeutic targets. 2006;10(2):267–280
  54. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005;8(3):179–183
  55. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22(20):7004–7014
  56. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12(1):122–127
  57. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–918
  58. Smith J, Ko Y-J, Dutcher J, et al. Update of a Phase I study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma. J Clin Oncol. 2004;22:385S;[Abstract]
  59. Hudes G, Carducci M, Tomczak P, et al. A Phase 3, randomized 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol. 2004;22(3):454–463[abstract]
  60. Amato R, Misellati A, Khan M, et al. A Phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol. 2006;24:224s;[Abstract]
  61. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–732
  62. Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5(10):2963–2970
  63. Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101(12):4878–4886
  64. Fox SB, Turley H, Cheale M, et al. Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumors and shuttles from cell membrane to nucleus. J Pathol. 2004;202(3):313–320
  65. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312(5):549–560
  66. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–434
  67. Rini BI, Halabi S, Taylor J, et al. Cancer and Leukemia Group B 90206: A randomized Phase III trial of interferon-α or interferon-α plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004;10(8):2584–2586
  68. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–2111
  69. Dupont J, Camastra D, Gordon M, et al. Phase I study of VEGF Trap in patients with solid tumors and lymphoma. Proceedings of the American Society for Clinical Oncology 2003;22;194 [Abstract]
  70. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24
  71. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–2524
  72. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib vs. interferon α in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124
  73. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res. 2007;13(6):1801–1809
  74. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505–2512
  75. Escudier B, Eisen T, Stalder WM, et al. Randomized Phase III trial of the RAF kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Proceedings of the American Society of Clinical Oncology Annual Meeting 2005; Orlando, FL.
  76. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase inhibitor, demonstrates antitumor activity in a Phase 2 study of cytokine refractory, metastatic renal cell cancer (RCC). J Clin Oncol. 2004;23:380;[Abstract]
  77. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012–2021
  78. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–410
  79. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111(9):1287–1295
  80. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103(2):159–165
  81. Knebelmann B, Ananth S, Cohen HT, et al. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 1998;58(2):226–231
  82. Prewett M, Rothman M, Waksal H, et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res. 1998;4(12):2957–2966
  83. Smith K, Gunaratnam L, Morley M, et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL–/– renal cancer. Cancer Res. 2005;65(12):5221–5230
  84. Motzer RJ, Amato R, Todd M, et al. Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003;21(1):99–101
  85. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004;22(15):3003–3015
  86. Ravaud A, Gardner J, Hawkins R, et al. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a Phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol. 2006;24:217s;[Abstract]
  87. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005;23(31):7889–7896
  88. Bukowski R, Kabbinavar F, Figlin R, et al. Results of a randomized Phase II trial of bevacizumab +/– erlotinib in mRCC. J Clin Oncol. 2006;24:18S;[Abstract]
  89. Van Veldhuizen PJ, Faulkner JR, Lara PN, et al. A Phase II study of flavopiridol in patients with advanced renal cell carcinoma: Results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol. 2005;56(1):39–45
  90. Grabmaier K, MC AdW, Verhaegh GW, et al. Strict regulation of CAIX(G250/MN) by HIF-1α in clear cell renal cell carcinoma. Oncogene. 2004;23(33):5624–5631
  91. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol. 2006;175(1):57–62
  92. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3(4):347–361
  93. Hayashi M, Sakata M, Takeda T, et al. Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1α is involved in trophoblast invasion under low-oxygen tension. Endocrinology. 2005;146(11):4682–4689
  94. Natali PG, Prat M, Nicotra MR, et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer. 1996;69(3):212–217
  95. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73
  96. Kung AL, Wang S, Klco JM, et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000;6(12):1335–1340
  97. Kong X, Lin Z, Liang D, et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1α. Mol Cell Biol. 2006;26(6):2019–2028

PII: S1078-1439(07)00320-1

doi: 10.1016/j.urolonc.2007.12.001

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 3 , Pages 238-245 , May 2009

Article Tools

* Image Usage & Resolution